

Neurodegenerative Disease:
Too much of a bad thing, kills you

John Hardy Ph.D. NIA

The law of mass action applied to neurodegenerative disease: a hypothesis concerning the etiology and pathogenesis of complex diseases

Andrew Singleton, Amanda Myers and John Hardy*

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Building 10, Room 6C103, MSC1589, Bethesda, MD 20892, USA

Received January 2, 2004; Revised February 3, 2004; Accepted February 9, 2004

Loci underlying autosomal dominant forms of most neurodegenerative disease have been identified: prion mutations cause Gerstmann Straussler syndrome and hereditary Creutzfeldt–Jakob disease, tau mutations cause autosomal dominant frontal temporal dementia, and α -synuclein mutations cause autosomal dominant Parkinson's disease. In all these cases, the pathogenic mutation is in the protein that is deposited in the diseased tissue and in these cases the whole protein is deposited. In Alzheimer's disease, mutations in APP or presenilin 1 or 2 cause autosomal dominant disease and these are the substrate and proteases, respectively, which are responsible for the production of the deposited peptide, A β . Thus, in all cases, the mutations lead to the disease by a mechanism that involves the deposition process. We briefly review this remarkably predictable biology, but also point out that it seems sporadic forms of all these diseases are predisposed to by genetic variability at the same loci, strongly suggesting that the quantity of the normal protein produced influences risk for the sporadic forms of the disease. The evidence for this assertion is strongest in Parkinson's disease (PD), where genetic variability in α -synuclein expression affects risk of developing disease, although the oldest evidence for the notion that increased expression of normal sequence protein can lead to disease comes from the observation of Alzheimer's disease in trisomy 21 cases. From these observations, we make predictions concerning the etiology and pathogenesis of neurodegenerative diseases in general.

Pathology of Diseases

- Alzheimer's disease: plaques ($A\beta$), tangles (tau) and often, Lewy bodies (α -synuclein).
- Prion disease: often PrP plaques; sometimes tangles; sometimes Lewy bodies.
- FTDP-17/Pick's disease: tangles or Pick bodies (3-repeat tau).
- Progressive Supranuclear Palsy and Corticobasal Degeneration (tangles).
- Parkinson's disease/Lewy body dementia: Lewy bodies.

A Prescient Suggestion

Biochem Biophys Res Commun. 1984 Aug 16;122(3):1131-5.

[Related Articles, Links](#)

Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein.

Glenner GG, Wong CW.

The cerebrovascular amyloid protein from a case of adult Down's syndrome was isolated and purified. Amino acid sequence analysis showed it to be homologous to that of the beta protein of Alzheimer's disease. This is the first chemical evidence of a relationship between Down's syndrome and Alzheimer's disease. It suggests that Down's syndrome may be a predictable model for Alzheimer's disease. Assuming the beta protein is a human gene product, it also suggests that the genetic defect in Alzheimer's disease is localized on chromosome 21.

: Brain. 1969 Mar;92(1):147-56.

Presenile dementia and Alzheimer's disease in mongolism.

Olson MI, Shaw CM.

: Ann Neurol. 1998 Mar;43(3):380-3.

[Related Articles](#), [Links](#)

Molecular mapping of Alzheimer-type dementia in Down's syndrome.

Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, Butler AC.

Department of Psychiatry, University of Birmingham, United Kingdom.

Previous research has hypothesized an association between Alzheimer's disease and the amyloid precursor protein (APP) gene found on chromosome 21. We report the case of a 78-year-old woman with Down's syndrome with partial trisomy 21 [46,XX,rec(21)dup q, inv(21) (p12q22.1)]. No evidence of Alzheimer's disease was found on neuropsychological, magnetic resonance imaging, and neuropathological assessment. The gene sequence for APP was present in only two copies. This case further supports the hypothesis that Alzheimer's disease is associated with trisomy for proximal chromosome 21q, including the APP gene.

Alzheimer's Disease

- Primary Deposited Protein is $A\beta$
- Genes for Mendelian Forms are
 - APP: precursor of $A\beta$
 - Presenilin 1 and 2: enzymes catalysing production of $A\beta$ from APP
- Tangle (tau) and Lewy Bodies (α -synuclein) are Secondary Pathologies.

nature
April 1999

APP-NTF ...KTEEEISEVKM D A E F

β secretase

α secretase

Exon 16
Exon 17

APP

Lumen

Exon 11
Exon 12

Cytosol

Exon 7
Exon 8

γ secretase

APP-CTF ...K

Exon 9
Exon 8

Presenilinase

γ secretase


APP-CTF ...K



Exon 9
Exon 8



Presenilinase

Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ -secretase activity

Michael S. Wolfe^{†††}, Weiming Xia^{††}, Beth L. Ostaszewski^{*}, Thekla S. Diehl^{*}, W. Taylor Kimberly^{*} & Dennis J. Selkoe^{*}







APP Probably a Locus for “Sporadic” Alzheimer’s Disease

Genetic variability at the amyloid- β precursor protein locus may contribute to the risk of late-onset Alzheimer’s disease

Fabienne Wavrant-De Vrièze^{a, f}, Richard Crook^a, Peter Holmans^{b, c}, Patrick Kehoe^b, Michael J. Owen^b, Julie Williams^b, Kim Roehl^{c, d}, Debomoy K. Laliiri^e, Shantia Shears^{c, d}, Jeremy Booth^{c, d}, William Wu^{c, d}, Alison Goate^{c, d}, Marie Christine Chartier-Harlin^f, John Hardy^{a, *}, Jordi Pérez-Tur^a

Neuroscience
Letters
July 1999

The Amyloid Precursor Protein Locus and Very-Late-Onset Alzheimer Disease


Jane M. Olson, Katrina A. B. Goddard, and Doreen M. Dudek

The American Journal of
Human Genetics

Oct. 2001

A full genome scan for late onset Alzheimer's disease

Patrick Kehoe⁺, Fabienne Wavrant-De Vrieze^{1,+}, Richard Crook^{1,+},
William S. Wu^{2,+}, Peter Holmans⁺, Iain Fenton, Gillian Spurlock, Nadine Norton,
Hywel Williams, Nigel Williams, Simon Lovestone³, Jordi Perez-Tur¹, Mike Hutton¹,
Marie-Christine Chartier-Harlin⁴, Shantia Shears², Kimberly Roehl², Jeremy Booth²,
Wendy Van Voorst², Dzanan Ramic², Julie Williams, Alison Goate², John Hardy¹ and
Michael J. Owen^{*}



Conclusion on Alzheimer's Disease

- Overexpression of APP in Down syndrome causes disease.
- Overproduction of $A\beta_{42}$ because of APP or presenilin mutations causes disease in a mendelian fashion.
- Genetic variability in 'normal' APP expression contributes to disease risk.
 - (not clear whether variability in presenilin expression also contributes).

Prion Diseases

- Primary protein deposit is PrP^{Sc}: sometimes as plaques, more often much more subtle.
- Hereditary (caused by prion gene mutations).
- Sporadic (of unknown cause)
- Infectious (iatrogenic, cannibalistic or infectious)
- Tangle (tau) and Lewy Bodies (α -synuclein) can be Secondary Pathologies.

The First Family with a Prion Mutation

Brain Res Mol Brain Res. 1990 Apr;7(3):273-6.

[Related Articles, Links](#)

An in-frame insertion in the prion protein gene in familial Creutzfeldt-Jakob disease.

Owen F, Poulter M, Shah T, Collinge J, Lofthouse R, Baker H, Ridley R, McVey J, Crow TJ.

Division of Psychiatry, Clinical Research Centre, Harrow, Middlesex, U.K.

In a pedigree with Creutzfeldt-Jakob disease we identified a 144-bp insertion in the open reading frame of the prion protein (PrP) gene. The insertion is in-frame and codes for 6 extra uninterrupted octapeptide repeats in addition to the 5 that are normally present in the N-terminal region of the protein. The possibility that this mutation may prove relevant to elucidating the mechanism of horizontal transmission of the spongiform encephalopathies is discussed.

: Lancet. 1991 Jun 15;337(8755):1441-2.

[Related Articles, Links](#)

Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease.

Collinge J, Palmer MS, Dryden AJ.

Department of Biochemistry and Molecular Genetics, St Mary's Hospital Medical School, London, UK.

The spongiform encephalopathy Creutzfeldt-Jakob disease (CJD) has been transmitted to man via administration of growth hormone and gonadotropin extracted from large pooled batches of human cadaveric pituitary glands. In the UK, 1908 individuals were exposed to potentially contaminated growth hormone, of whom 6 have so far manifested CJD. Examination of the prion protein genes of all these cases and of a single case of gonadotropin-related CJD showed that 4 had the uncommon valine 129 homozygous genotype indicating genetic susceptibility to prion infection. Such genetic susceptibility may be important in the aetiology of sporadic CJD disease.

Variant Creutzfeldt-Jakob disease

John Collinge

[The Lancet](#)

[Volume 354, Issue 9175](#), 24 July 1999, Pages 317-323

“The unremarkable history of exposure to BSE among patients with variant CJD to date suggests that these susceptibility factors are more important than the degree of exposure. Susceptibility could be genetic or related to one or more cofactors. All patients with variant CJD analysed to date have been *PRNP* codon 129 methionine homozygotes. All cattle studied are homozygous for methionine at the corresponding bovine codon. About 38% of the normal white population are, however, of this *PRNP* genotype.”

Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease.

Palmer MS, Dryden AJ, Hughes JT, Collinge J.

Department of Biochemistry and Molecular Genetics, St Mary's Hospital Medical School, London, UK.

The human prion diseases, Creutzfeldt-Jakob disease (CJD) and Gerstmann-Straussler syndrome (GSS), are neurodegenerative diseases that are unique in being both infectious and genetic. Transmission of both diseases and the animal spongiform encephalopathies (for example, scrapie and bovine spongiform encephalopathy) to experimental animals by intracerebral inoculation with brain homogenates is well documented. Despite their experimental transmissibility, missense and insertional mutations in the prion protein gene are associated with both GSS and familial CJD, demonstrating that the human familial cases are autosomal dominant diseases. More than 80% of CJD cases occur sporadically, however, and are not known to be associated with mutations. Here we report that 21 of 22 sporadic CJD cases and a further 19 of 23 suspected sporadic CJD cases are homozygous at the polymorphic amino-acid residue 129; 51% of the normal population are heterozygous at this site. We argue that homozygosity predisposes towards sporadic CJD and that this directly supports the hypothesis that interaction between prion protein molecules underlies the disease process.

Am. J. Hum. Genet. 69:1225-1235, 2001

Sporadic—but Not Variant—Creutzfeldt-Jakob Disease Is Associated with Polymorphisms Upstream of *PRNP* Exon 1

Simon Mead,¹ Sukhvir P Mahal,¹ John Beck,¹ Tracy Campbell,¹ Martin Farrall,² Elizabeth Fisher,¹ and John Collinge¹


Prion Disease Conclusions

- Mutations in prion gene cause mendelian disease.
- Homozygosity at codon 129 predisposes to infectious disease: whether it is MM or VV depends on the sequence of the infecting prion.
- Homozygosity of either allele predisposes to sporadic CJD.
- Particular promoters, presumably high expressing ones, also predispose to sporadic CJD.
- But the promoter association does not hold up for infectious disease.
- Thus, the mechanism of initiation of infectious disease is different from that of sporadic disease (*the former is not concentration dependent but the latter is?*)

Disease with *only* Tau Pathology

- FTDP-17 (previously, many families would have been called Pick's disease): mendelian disease with variable pathology: tangles, Pick bodies or wispy tau filaments.
- Progressive Supranuclear Palsy, Corticobasal degeneration, Argyrophilic Grain Disease
- Parkinson's Dementia Complex of Guam
- Many other rare diseases including von Economo's disease and subacute sclerosing panencephalitis.


The microtubule associated protein tau



Tau 3 repeat protein isoforms



Tau 4 repeat protein isoforms



Tau Is a Candidate Gene for Chromosome 17 Frontotemporal Dementia

Parvoneh Poorkaj, PhD,*† Thomas D. Bird, MD,*‡ Ellen Wijsman, PhD,§¶|| Ellen Nemens, MS,*
Ralph M. Garruto, PhD,# Leojean Anderson, BS,* Athena Andreadis, PhD,** Wigbert C. Wiederholt, MD,††
Murray Raskind, MD,‡‡§§ and Gerard D. Schellenberg, PhD*†‡¶¶

Annals of Neurology


June 1998

Association of missense and 5'-splice-site mutations in *tau* with the inherited dementia FTDP-17


nature
June 1998

Mike Hutton¹, Corinne L. Lendon², Patrizia Rizzu^{3,4}, Matt Baker¹,
Susanne Froelich^{3,5}, Henry Houlden¹, Stuart Pickering-Brown⁶,
Sumi Chakraverty², Adrian Isaacs¹, Andrew Grover¹,
Jennifer Hackett¹, Jennifer Adamson¹, Sarah Lincoln¹,
Dennis Dickson¹, Peter Davies⁷, Ronald C. Petersen⁸,
Martijn Stevens⁴, Esther de Graaff³, Erwin Wauters³,
Jeltje van Baren³, Marcel Hillebrand³, Marijke Joesse³,
Jennifer M. Kwon⁹, Petra Nowotny², Lien Kuei Che², Joanne Norton⁹,
John C. Morris⁹, Lee A. Reed¹⁰, John Trojanowski¹⁰, Hans Basun⁵,
Lars Lannfelt⁵, Michael Neystat¹¹, Stanley Fahn¹¹, Francis Dark¹²,
Tony Tannenberg¹³, Peter R. Dodd¹⁴, Nick Hayward¹⁵,
John B. J. Kwok¹⁶, Peter R. Schofield¹⁶, Athena Andreadis¹⁷,
Julie Snowden¹⁸, David Craufurd¹⁹, David Neary¹⁸, Frank Owen⁶,
Ben A. Oostra³, John Hardy¹, Alison Goate², John van Swieten⁴,
David Mann²⁰, Timothy Lynch¹¹ & Peter Heutink³

Tau Exon 10 3' splice site mutations increase U1 snRNP binding and splicing of Exon 10



Evolution of Human *tau* haplotypes (no recombination between H1/H2)



(+)/(-) indicates location of intronic deletion 5' of E10

Association of an extended haplotype in the *tau* gene with progressive supranuclear palsy

Matt Baker, Irene Litvan¹, Henry Houlden, Jennifer Adamson, Dennis Dickson, Jordi Perez-Tur, John Hardy, Timothy Lynch², Eileen Bigio³ and Mike Hutton*

**Human
Molecular
Genetics**
April 1999

Neurology 2001;56:1702-1706


© 2001 [American Academy of Neurology](#)

Articles


Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype

H. Houlden, MRCP; M. Baker, BSc; H.R. Morris, MRCP; N. MacDonald, MBBS; S. Pickering-Brown, PhD; J. Adamson, BS; A.J. Lees, MD; M.N. Rossor, MD; N.P. Quinn, MD; A. Kertesz, MD; M.N. Khan, MSc; J. Hardy, PhD; P.L. Lantos, MD; P. St. George-Hyslop, MD, FRCP(C); D.G. Munoz, MD; D. Mann, MD; A.E. Lang, MD; C. Bergeron, MD; E.H. Bigio, MD; I. Litvan, MD; K.P. Bhatia, MD; D. Dickson, MD; N.W. Wood, FRCP; and M. Hutton, PhD

Worldwide Distribution of Tau Haplotype



Results



- LD extends almost the same distance in all populations (1.6Mb)
 - Some breakdown at the teleomeric edge

Inversion

ARTICLES

nature
genetics

A common inversion under selection in Europeans

Hreinn Stefansson^{1,3}, Agnar Helgason^{1,3}, Gudmar Thorleifsson¹, Valgerdur Steinthorsdottir¹, Gisli Masson¹, John Barnard², Adam Baker¹, Aslaug Jonasdottir¹, Andres Ingason¹, Vala G Gudnadottir¹, Natasa Desnica¹, Andrew Hicks¹, Arnaldur Gylfason¹, Daniel F Gudbjartsson¹, Gudrun M Jonsdottir¹, Jesus Sainz¹, Kari Agnarsson¹, Birgitta Birgisdottir¹, Shyamali Ghosh¹, Adalheidur Olafsdottir¹, Jean-Baptiste Cazier¹, Kristleifur Kristjansson¹, Michael L Frigge¹, Thorgeir E Thorgeirsson¹, Jeffrey R Gulcher¹, Augustine Kong^{1,3} & Kari Stefansson^{1,3}

Haplotype dating

- Inversion/LD block implies distinct evolutions for each haplotype because there is suppressed recombination between the two haplotype clades
- Performed 2 analyses to determine the evolutionary distance between H1 and H2

Comparison of chimp and human sequence

Position	dbSNP ID	Chimp	H1	H2
41301910	rs1078830	C	T	C
41307507	rs2055794	A	G	A
41333623	rs1864325	C	C	T
41334330	rs1560310	G	G	A
41336326	rs3885796	C	T	G
41354620	rs767058	C	C	G
41409284	rs2217394	G	A	G
41411483	rs754512	T	T	A
41429726	rs1052553	G	A	G
41432502	sthQ7R	G	A	G
41442488	<i>ins/del9</i>	+	+	-
41445400	rs733966	C	C	T
41457408	rs9468	C	T	C
41461242	rs7521	G	A	G

- neither haplotype is the founder of the other, since chimp at some level resembles either haplotype
- **H1/H2 diverged from ~3 million years ago (also DeCode and Antwerp data)**

Slippage of dinucleotide repeat markers


Marker name	Location	Major Allele Size	Major allele frequency	Predicted Age in Generations (Years)
Tau Hap 2	44752820	182	75%	513 (12,825)
Tau Hap 3	45289761	183	74%	542 (13,550)
Tau Hap 5	44423308	258	86%	267 (6,675)
Tau Hap 6	44439826	496	87%	243 (6,075)
Tau Hap 7	44475319	240	62%	868 (21,700)

- Assuming that H2 is a single founder event and an average of 25 generations for each slippage event, typed 13 CEPH H2 homozygotes with microsatellite markers mapping to the region.
- **The age of H2 in *H. sapiens* is ~10,000-30,000 years based on distribution and slippage.**


H2 has been re-introduced once exclusively into European *H. sapiens* populations

- Contradictory evolutionary evidence:
 - H1 and H2 diverged ~ 3M years ago
 - Yet, based on slippage analysis H2 is a recent haplotype within *H. sapiens* (10-30K years ago)
- Further evidence:
 - H2 haplotype has reduced diversity compared with H1
 - H2 distribution reflects the spread of European populations and is not seen within Asian and most African chromosomes

H1, not H2 is Inverted!




Model of the evolution of the MAPT locus






"Neanderthals have moved in next door!"

Tagging SNPs Selection



- 25 SNPs spanning the entire locus were selected from the CEPH database (www.hapmap.org)
- Using the program Tagit (popgen.biol.ucl.ac.uk/software) 5 SNPs were identified that captured the haplotype diversity of the *MAPT* locus

Dissecting H1 further...




Associations with PSP... and AD

	Controls	Alzheimer Disease	PSP
H2a	23	23	6
H1b	13	15	14
H1c	9	14	24
Others	55	48	56
(n) 'p'	(272)	(360)	(321)
		0.006	0.000006

MAPT and meta-analysis

<http://www.alzforum.org/res/com/gen/alzgene/default.asp>



Primary Tauopathies

- Mutations in the opening reading frame or in the exon 10 splice area cause mendelian tau disease (FTDP-17): the precise tau pathology is largely dependent on the mutation.
- Sporadic tangle diseases, PSP and CBD are predisposed to by the tau H1 haplotype.
- Weaker association of same haplotypes with Alzheimer's disease.
- Other sporadic tangle diseases are either not assessed (too rare) or occur in populations without an H2 allele (Guam).
- Not clear whether haplotype association reflects differences in splicing or in expression (though overexpressing mice get tangles).

Diseases with *only* Lewy Bodies

- Parkinson's disease
- Lewy body dementia

Science
June 1997

Mutation in the α -Synuclein Gene Identified in Families with Parkinson's Disease

Mihael H. Polymeropoulos,* Christian Lavedan†, Elisabeth Leroy†, Susan E. Ide, Anindya Dehejia, Amalia Dutra, Brian Pike, Holly Root, Jeffrey Rubenstein, Rebecca Boyer, Edward S. Stenroos, Settara Chandrasekharappa, Aglaia Athanassiadou, Theodore Papapetropoulos, William G. Johnson, Alice M. Lazzarini, Roger C. Duvoisin, Giuseppe Di Iorio, Lawrence I. Golbe, Robert L. Nussbaum

The New Mutation, E46K, of α -Synuclein Causes Parkinson and Lewy Body Dementia

Juan J. Zarranz, MD, PhD,¹ Javier Alegre, MD,² Juan C. Gómez-Esteban, MD,¹ Elena Lezcano, PhD,¹ Raquel Ros, PhD,² Israel Ampuero, PhD,² Lídice Vidal, PhD,² Janet Hoenicka, PhD,² Olga Rodríguez, MD,³ Begoña Atarés, MD,⁴ Verónica Llorens, MD,⁵ Estrella Gomez Tortosa, MD, PhD,^{2,6} Teodoro del Ser, MD, PhD,⁷ David G. Muñoz, MD, PhD,² and Justo G. de Yébenes, MD, PhD^{2,6}

Familial parkinsonism and dementia with cortical and subcortical Lewy bodies is uncommon, and no genetic defect has been reported in the previously described sibships. We present a Spanish family with autosomal dominant parkinsonism, dementia, and visual hallucinations of variable severity. The postmortem examination showed atrophy of the substantia nigra, lack of Alzheimer pathology, and numerous Lewy bodies which were immunoreactive to α -synuclein and ubiquitin in cortical and subcortical areas. Sequencing of the α -synuclein gene showed a novel, nonconservative E46K mutation in heterozygosis. The E46K mutation was present in all affected family members and in three young asymptomatic subjects, but it was absent in healthy and pathological controls. The novel mutation, that substitutes a dicarboxylic amino acid, glutamic acid, with a basic amino acid such as lysine in a much conserved area of the protein, is likely to produce severe disturbance of protein function. Our data show that, in addition to the previously described hereditary α -synucleinopathies, dementia with Lewy bodies is related to mutation of α -synuclein.

**Human
Molecular
Genetics**
Aug. 2001

**α -synuclein gene haplotypes are associated with
Parkinson's disease**

Matt Farrer, Demetrius M. Maraganore¹, Paul Lockhart, Andrew Singleton, T.G. Lesnick²,
Mariza de Andrade², Andrew West, Rohan de Silva³, John Hardy* and Dena Hernandez


Hum Genet (2003) 113:426–431
DOI 10.1007/s00439-003-1002-9


ORIGINAL INVESTIGATION

Ornit Chiba-Falek · Jeffrey W. Touchman
Robert L. Nussbaum

**Functional analysis of intra-allelic variation at NACP-Rep1
in the α -synuclein gene**

Iowa Kindred Structure







Laboratory of Neurogenetics, National Institute on Aging




Diffuse α -synuclein pathologies in male patient: abnormal neuronal and glial inclusions and processes


Globus pallidus







Substantia nigra



Hippocampus



Chromosomal Spreads (FISH)



Lewy Bodies Disease

Conclusions


- Mutations in α -synuclein can cause either mendelian Parkinson's disease or Lewy Body dementia, sometimes both in the same family.
- Triplication (overall doubling) of the α -synuclein locus causes disease onset in the 30's (duplication of the locus, causes disease in the 50's)
- Genetic variability in the normal promoter contributes to risk of sporadic disease with high expression promoters being more prone to disease.

Overall Conclusions

- Analysis of autosomal dominant forms of neurodegenerative diseases in which there is pathological deposition reveal that the causative locus encodes the protein which is deposited (most cases) or the enzymes responsible for the liberation of the deposited peptide (presenilins).
- Normal genetic variability at these same loci contribute to the risk of sporadic forms of these diseases: most likely, high expressors are predisposed to disease.
- Predictions and Implications
 - Deposition is *clearly* important.
 - SOD and sporadic ALS?
 - Genetic variability in degradation may also contribute to risk?


Whole Genome Study For AD

(presently underpowered ~180 cases and controls)



Loss of Heterozygosity

(10% North American Controls Show Evidence for Consanguinity)



Sample Whole Genome Data

Chromosome 5 Control Male of 65 years

